Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARIPIPRAZOLE vs ARAKODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A receptors.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Schizophrenia,Acute manic and mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Adjunctive treatment of major depressive disorder,Irritability associated with autistic disorder,Tourette's disorder
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
Oral: 10-15 mg once daily; initial and target dose 10-15 mg; maximum 30 mg/day. IM: 9.75 mg single dose, then 5.25-9.75 mg every 2 hours if needed; maximum 30 mg/day.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
Aripiprazole has a terminal elimination half-life of approximately 75 hours in extensive CYP2D6 metabolizers and about 146 hours in poor metabolizers. The active metabolite, dehydro-aripiprazole, has a half-life of about 94 hours. This long half-life allows for once-daily dosing and gradual achievement of steady state (14 days in extensive metabolizers).
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Primarily hepatic via CYP2D6 and CYP3A4.
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Aripiprazole is extensively metabolized primarily by the liver via CYP2D6 and CYP3A4. Approximately 25% of the dose is excreted unchanged in urine, and about 55% in feces. The major metabolite, dehydro-aripiprazole, accounts for about 40% of the AUC and is also excreted in urine and feces.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Aripiprazole is >99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. High protein binding means that changes in protein levels (e.g., hypoalbuminemia) can affect free drug concentration.
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
The volume of distribution (Vd) for aripiprazole is approximately 4.9 L/kg, indicating extensive tissue distribution (well beyond total body water). This large Vd suggests significant partitioning into tissues, which contributes to the long half-life.
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
Oral: The absolute bioavailability of aripiprazole tablets is approximately 87%. Bioavailability is not significantly affected by food. Intramuscular immediate-release: Bioavailability is 100% for the IM formulation relative to oral. The long-acting injectable (aripiprazole lauroxil) has a bioavailability of about 100% compared to oral aripiprazole after reaching steady state.
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). For severe renal impairment (Cr Cl <15 m L/min), use with caution; limited data suggests no adjustment needed, but monitor tolerability.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Child-Pugh Class A (mild): no adjustment. Child-Pugh Class B (moderate): start at 10 mg/day; titrate cautiously. Child-Pugh Class C (severe): avoid use; if unavoidable, start at 5 mg/day and titrate slowly.
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
Schizophrenia (≥13 years): 10-15 mg/day initially; target 15 mg/day; max 30 mg/day. Irritability associated with autistic disorder (6-17 years): 5-10 mg/day; start at 2.5 mg/day for ≥30 kg and 5 mg/day for <30 kg; titrate gradually. Tourette's disorder (6-18 years): 5-10 mg/day; start at 2.5 mg/day for <50 kg and 5 mg/day for ≥50 kg; max 10 mg/day.
Safety and efficacy not established in pediatric patients (<18 years).
Initiate at 10 mg/day; titrate slowly due to increased sensitivity and risk of hypotension, sedation, and extrapyramidal symptoms. Maximum 15 mg/day in elderly patients with psychosis. Consider lower initial doses (2-5 mg/day) in frail patients.
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
Increased risk of death in elderly patients with dementia-related psychosis.
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
Increased risk of cerebrovascular events in elderly with dementia, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, cognitive and motor impairment, and body temperature dysregulation.
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
Hypersensitivity to aripiprazole or any components of the formulation.
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
No significant food interactions. Absorption unaffected by food. Avoid grapefruit juice as it may increase aripiprazole levels via CYP3A4 inhibition.
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses, but increased risk of neural tube defects at high doses. Second/third trimesters: Possible risk of extrapyramidal symptoms or withdrawal in neonates; risk of gestational diabetes and weight gain. Overall, not a major human teratogen but risk-benefit assessment required.
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
Aripiprazole is excreted into breast milk; estimated relative infant dose is 1-8% of maternal weight-adjusted dose. M/P ratio not established. Monitor infant for sedation, poor feeding, and extrapyramidal symptoms. Consider benefits of breastfeeding vs. potential risks.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
Increased clearance and volume of distribution in pregnancy may necessitate dose increases, especially in the third trimester. Therapeutic drug monitoring if available; adjust based on clinical response and tolerability. Postpartum, reduce to prepregnancy dose to avoid toxicity.
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
Aripiprazole is a partial dopamine agonist, distinguishing it from typical antipsychotics. Monitor for akathisia, especially during titration. QT prolongation risk is lower than with other antipsychotics, but ECG is recommended in patients with cardiac risk. Tardive dyskinesia risk exists but may be lower than with typical agents. Avoid abrupt discontinuation to prevent withdrawal dyskinesias. Metabolized by CYP2D6 and CYP3A4; dose adjustments needed with CYP2D6 inhibitors or poor metabolizers. May cause orthostatic hypotension; titrate slowly. Weight gain and metabolic effects are less pronounced than with olanzapine or clozapine, but still monitor weight, lipids, and glucose.
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
Take once daily without regard to meals. Swallow tablets whole, do not crush or chew.,May cause dizziness or drowsiness, especially when starting; avoid driving until you know how it affects you.,Do not stop taking suddenly without consulting your doctor, as this may cause withdrawal symptoms.,Report any restlessness, muscle stiffness, fever, or unusual movements to your doctor immediately.,Limit alcohol intake as it can increase side effects like drowsiness.,Inform your doctor of all medications you take, including over-the-counter drugs and supplements.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double up.,Regular blood tests may be needed to check for effects on blood sugar and cholesterol.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
"Aripiprazole, a partial dopamine D2 and serotonin 5-HT1A agonist, may have its adverse effects potentiated by methsuximide, a succinimide anticonvulsant that inhibits CYP3A4. This can lead to increased aripiprazole plasma concentrations, raising the risk of extrapyramidal symptoms, sedation, and QT prolongation. Clinical outcomes include heightened neurotoxicity and potential for arrhythmias."
"Concurrent use of aripiprazole and clonazepam increases the risk of central nervous system (CNS) depression, including excessive sedation, dizziness, ataxia, and impaired cognitive or motor function. This additive pharmacodynamic interaction results from the combined depressant effects on the CNS mediated by GABAergic potentiation from clonazepam and dopaminergic/serotonergic modulation from aripiprazole. Patients may experience heightened somnolence, psychomotor slowing, and an increased risk of falls, particularly during initiation or dose escalation."
"Aripiprazole, an atypical antipsychotic with partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at 5-HT2A receptors, can induce orthostatic hypotension, particularly during initial titration. This hypotensive effect may be additive when combined with moexipril, an ACE inhibitor that lowers blood pressure by inhibiting angiotensin II production. Concomitant use increases the risk of symptomatic hypotension, including dizziness, syncope, and falls, especially in elderly or volume-depleted patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARIPIPRAZOLE vs ARAKODA, answered by our medical review team.
ARIPIPRAZOLE is a Atypical Antipsychotic that works by Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A receptors.. ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARIPIPRAZOLE and ARAKODA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARIPIPRAZOLE is: Oral: 10-15 mg once daily; initial and target dose 10-15 mg; maximum 30 mg/day. IM: 9.75 mg single dose, then 5.25-9.75 mg every 2 hours if needed; maximum 30 mg/day.. The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARIPIPRAZOLE and ARAKODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARIPIPRAZOLE is classified as Category A/B. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses, but increased risk of neural tube defects at high doses. Second/third trimesters: P. ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.